- Select a blog category
By Krissie Ferris, Research Analyst, Centre for Health Solutions
This week is the UK’s national Mental Health Awareness Week (MHAW). This year’s theme is ‘Nature’ and how connecting with the natural world can support ‘good mental health’.1 During the long months of the pandemic, research by the Mental Health Foundation found that millions of people have turned to nature to help get through lockdowns, their findings showing that connecting with nature can be both preventative as well as aid recovery from poor mental health. Its research found that going for walks outside was one of the top coping strategies during lockdowns, and 45 per cent reported that being in green spaces has been vital for their mental health.2 However, the pandemic has highlighted huge disparities in access to natural spaces, especially for people living in urban areas, as well as those on lower incomes. This blog explores how a ‘nature in all policies’ approach could improve the nation’s health and wellbeing.
By Karen Taylor, Director, and Maria João Cruz, PhD, Assistant Research Manager, Deloitte Centre for Health Solutions
Trust is critical for the biopharma industry, from influencing their chances of gaining and maintaining customers to their ability to recruit talent. Consumer’s trust in biopharma also gives the industry the incentive to innovate to provide life-saving therapies. Yet, biopharma still ranks as one of the least trusted industries, even though consumer polls show that the COVID-19 pandemic has helped improved trust. In January 2021, Deloitte’s US and UK Centres for Health Solutions conducted consumer research, using digital focus group discussions in four countries (the US, UK, India and South Africa) seeking to answer crucial questions around consumer trust in pharma. This week marks the launch of our research report, Overcoming biopharma’s trust deficit: Why people mistrust the biopharma industry – and what to do about it, and this blog highlights our take on the report and what companies can do to build and maintain trust.
By Karen Taylor, Director, Centre for Health Solutions and Michel De Ridder, Partner, Deloitte Belgium, Regulatory compliance
Last week my colleague Michel De Ridder and I participated in the annual MedTech Europe Forum 2021, where we delivered a presentation on our Deloitte Centre for Health Solutions research report 'Predicting the future of healthcare and life sciences in 2025: The future unmasked'. Our focus was on our sixth prediction 'MedTech and the IOMT are crucial drivers of value-based care'. However, we also discussed the implications of findings in our November 2020 research paper, ‘Winning in the future of MedTech’, underpinned by our global campaign on the Future of Health.i Following our presentation, we ran an ‘Ask the expert session’ to discuss emerging issues in relation to IP management. This week’s blog highlights the main themes that we discussed and explores the implications for MedTech companies’ role in the future of health.
By Dr. Maria João Cruz, PhD, Assistant Research Manager, Deloitte Centre for Health Solutions
This week marks the launch of the fifth report in our Intelligent biopharma series, which highlights the role of artificial intelligence (AI) in accelerating and driving digital transformation across the biopharma value chain. This report, Intelligent drug launch and commercial: Optimising value through AI, focuses on how companies can use AI to radically change and improve drug launches and their commercial models. The report also reflects on the challenges and disruptions caused by the COVID-19 pandemic and the response of commercial teams, including adapting new marketing and engagement channels to meet the needs of the different stakeholders.
By Karen Taylor, Director Deloitte Centre for Health Solutions
Deloitte’s, 2021 global health care outlook: Accelerating industry change, explores the six critical foundational shifts driving change in the health care sector. These shifts, which have been exacerbated by the COVID-19 pandemic, comprise consumers and the human experience; care model innovation; digital transformation and interoperable data; socio-economic shifts; public-private collaborations; and the future of work and talent. How governments understand and respond to these issues will shape their ability to navigate through recovery and thrive post-pandemic. Over the next couple of months, as part of our blog series, we will examine each shift in turn. This week’s blog considers the future of work and talent, starting with the challenges pre-pandemic, the impact of the pandemic and need for adaptable and resilient workforce for the future.
By Emily May, Research Analyst, Deloitte Centre for Health Solutions
In March 2020, the UK government established the COVID-19 Genomics UK Consortium (COG-UK) with an initial remit to contribute to the UK’s response to the COVID-19 pandemic by sequencing the SARS-CoV-2 genomes, identifying new variants of the virus, and combining this with clinical information to inform public health actions and policy decisions.1 To mark its first anniversary we explore some of the critical breakthroughs arising from COG-UK’s genomics research and how this is paving the way for a future in which genomics applications are fully integrated into public health.
By Catherine Skilton, UK Public Sector Lead Partner for Integrated Care Systems and ConvergeHEALTH, Deloitte’s healthcare software products business
The shift towards a digital-first healthcare system has accelerated during the COVID-19 pandemic, demonstrating that, given the opportunity for better access, people will engage in new ways with their health and wellbeing services. However, while many individuals have developed a greater awareness of their health and taken meaningful steps to improve it, the pandemic has exposed, and potentially increased inequalities in health outcomes due, in part, to inequalities in access to the technologies, connectivity, and digital and/or health literacy needed to improve outcomes equitably. Moreover, for some individuals improving health and wellbeing may not be their top priority, so new ways of engaging people, grounded in behavioural science, are required to optimise engagement with different segments of the population.
By Dr. Stephanie Allen, Deloitte Global Health Care sector leader, Deloitte Australia
Every year Deloitte produces a report exploring the outlook for the healthcare sector. This year’s report, 2021 global health care outlook: Accelerating industry change explores the foundational shifts arising from and being exacerbated by COVID-19’s spread. Examples include consumers’ increasing involvement in health care decision-making; the rapid adoption of virtual health and other digital innovations; the push for interoperable data and data analytics use; and unprecedented public-private collaborations in vaccine and therapeutics development. Amid these dynamics, governments, health care providers, payers, and other stakeholders around the globe are being challenged to quickly pivot, adapt, and innovate. This week’s blog repurposes a blog by Stephanie Allen, our Deloitte Global Health Care sector leader, Deloitte Australia, which appeared first on our US Center for Health solutions Health Forward Blog site.
By Glenn Snyder, principal, MedTech Practice leader, Deloitte Consulting LLP, and Arod Balissa, manager, Deloitte Catalyst | Tel Aviv
As we highlight in the six prediction of our report ‘The future unmasked, predicting the future of healthcare and life sciences in 2025’, MedTech companies have a critical role in driving the future of health, using transformative technology to enhance products and services, enabling 4P medicine and driving value-based care. Companies are also beginning to develop sophisticated data analytics capabilities and work more closely with end users to leverage AI and robotic technologies to improve patient outcomes. This week, we are sharing a blog by Glenn Snyder, Deloitte’s US MedTech Practice leader and Arod Balissa a manager at the Tel Aviv Deloitte Catalyst, in which they explore how MedTech is transforming health and care in Israel.
By Krissie Ferris, Research Analyst, Deloitte Centre for Health Solutions, and Shivani Maitra, Partner, Human Capital, Life Sciences and Health Care
Monday 8th March was International Women’s Day (IWD), celebrating the social, economic, cultural, and political achievements of women. The day also marked a call to action for accelerating women's equality.1 It also recognised that while the COVID-19 pandemic has had a detrimental impact on society as a whole, its impact has increased a number of pre-existing gender inequalities. Specifically, research suggests women are twice as likely as men to have lost their jobs, more likely to have been furloughed and have also been required to take on additional caring responsibilities.2 Women are also more likely work in industries that have been severely impacted by the COVID-19 outbreak.3 The theme of this year’s IWD is #ChooseToChallenge and in this week’s blog we explore how the voice of women can be used to challenge work and employment inequalities and create a fairer society.